To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage

NCT06376474 | Recruiting Phase 1

• 1 other identifier: HM005PS1S06
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study was to evaluate the pharmacokinetics of Hemay 005 tablets in subjects with mild, moderate liver impairment and normal liver function, and to provide a basis for the formulation of clinical medication regimens for patients with liver impairment.

Conditions

Psoriasis

Outcome Measures

Primary Outcomes (6)

• Relevant pharmacokinetic parameters，Peak Plasma Concentration（Cmax）

  All subjects who receive the drug will be analyzed for pharmacokinetic

  Day1-Day6

• Relevant pharmacokinetic parameters，Area under the plasma concentration versus time curve（AUC0-t）

  All subjects who receive the drug will be analyzed for pharmacokinetic

  Day1-Day6

• Relevant pharmacokinetic parameters，Area under the curve from time 0 extrapolated to infinite time (AUC0-inf)

  All subjects who receive the drug will be analyzed for pharmacokinetic

  Day1-Day6

• Relevant pharmacokinetic parameters，half-life (T1/2)

  All subjects who receive the drug will be analyzed for pharmacokinetic

  Day1-Day6

• Relevant pharmacokinetic parameters，clearance (CL/F)

  All subjects who receive the drug will be analyzed for pharmacokinetic

  Day1-Day6

• Relevant pharmacokinetic parameters，volume of distribution (Vz/F)

  All subjects who receive the drug will be analyzed for pharmacokinetic

  Day1-Day6

Study Arms (3)

Mild liver damage group

EXPERIMENTAL

15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

Drug: Hemay005

Moderate liver damage group

EXPERIMENTAL

15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

Drug: Hemay005

Healthy subjects

EXPERIMENTAL

15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

Drug: Hemay005

Interventions

Hemay005 DRUG

15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

Also known as: Hemay005 tablet

Healthy subjects; Mild liver damage group; Moderate liver damage group

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Fully understand the content, process and possible adverse reactions of the trial before the trial, and be able to complete the study and sign the informed consent according to the requirements of the trial protocol;
• \. Adults of both sexes aged from 18 to 70 years old (both ends, based on written informed consent);
• \. The body weight of male subjects should not be less than 50 kg and the body weight of female subjects should not be less than 45 kg. Body mass index (BMI) : 19-32 kg/m2 (including cut-off value);
• \. chronic stable liver impairment (no clinically significant change in disease status as judged by the investigator to have occurred for at least 28 days (or up to 14 days for patients with moderate liver function) before taking the study drug) due to primary liver disease (e.g., autoimmune hepatitis, nonalcoholic fatty liver disease, alcoholic liver disease, etc.); Patients were classified as grade A/mild (Child-Pugh score: 5-6) or grade B/moderate (Child-Pugh score: 7-9) according to the Child-Pugh classification within 72 hours before taking the study drug; Among them, the researchers used standard diagnosis and treatment methods, combined with the patient's past medical history, laboratory tests, liver biopsy or imaging examination and other documents to diagnose chronic liver function impairment, and then evaluated according to the Child-Pugh classification.
• \. (Inquiry) patients who have a stable medication plan for the treatment of liver function impairment, complications, and other concomitant diseases for at least 28 days (or 14 days for patients with moderate liver function) before taking the study drug, and who do not need to adjust the medication (including the type, dose, or frequency of medication); Or those who do not use drugs;
• In addition to liver function damage and complications, the investigators were in good physical condition according to medical history inquiry, vital signs, physical examination, laboratory tests (blood routine, urine routine, stool routine, blood biochemistry, coagulation function, blood pregnancy (only female), 12-lead electrocardiogram, chest X-ray, abdominal color Doppler ultrasound, electroencephalogram, etc.), and no other clinically significant abnormalities.

You may not qualify if:

• \. (Inquiry) The subject has any of the following conditions: previous liver transplantation; Severe portal hypertension or transsurgical portosystemic shunt; Patients with suspected or confirmed liver cancer or other malignant tumors; Patients with hepatorenal syndrome; Biliary cirrhosis, biliary obstruction, cholestatic liver disease and other diseases that seriously affect bile excretion; Patients with complications such as hepatic encephalopathy (according to Child-Pugh criteria), liver failure, esophageal and gastric varices bleeding, severe/advanced ascites or pleural effusion requiring puncture drainage and albumin supplementation, who were considered by the investigator to be unsuitable;
• \. (Inquiry) In addition to the disease causing liver function impairment, patients with serious acute or chronic diseases of other important organs within 1 year before screening, including but not limited to neuropsychiatric, gastrointestinal, respiratory, urinary, endocrine, hematological, immune and other diseases, judged by the investigator to be not suitable for the trial;
• \. (Inquiry) Any of the following occurred within 6 months prior to study entry: Myocardial infarction, Congenital long QT syndrome, Torsades de pointes (including sustained ventricular tachycardia and ventricular fibrillation), right bundle branch block and left anterior hemiblock (bifascicular block), Unstable angina pectoris, coronary artery/peripheral artery bypass grafting, New York Heart Association (NYHA) class III or IV congestive heart failure, cerebrovascular accident, transient ischemic attack, or pulmonary embolism;
• \. (asking) a history of depression or suicidal tendencies;
• \. (Inquiry) patients who had severe gastrointestinal diseases (except secondary gastrointestinal diseases caused by hepatitis) or had digestive system surgery within 3 months before screening, and the investigators thought that the absorption of drugs was affected;
• \. (Inquiry) patients who lost blood or donated more than 400mL of blood within one month before screening, or received red blood cell transfusion;
• \. (Inquiry) Liver function fluctuation (e.g., active hepatitis), rapid deterioration (e.g., advanced ascites, fever, active gastrointestinal bleeding), CTCAE 5.0 common adverse event grade ≥ 2, ongoing arrhythmia, atrial fibrillation of any grade during screening;
• The screening laboratory test results met any of the following: (a) alanine aminotransferase (ALT) \>5 times the normal value; (b) neutrophil count \<1.0×109/L; (c) hemoglobin (HGB) \<90 g/L; (d) platelet level \<50×109/L; (e) subjects with alpha-fetoprotein (AFP) \>50 ng/mL and suspected hepatocellular carcinoma;
• \. (Inquiry) patients with specific allergic history (asthma, urticaria, eczema, etc.), or allergic condition (such as allergic to two or more drugs, foods or pollens), or known allergic to PDE4 inhibitors (such as apast, roflumilast, etc.);
• \. (inquiry) those who had a history of drug abuse in the past 5 years or drug abuse in the past 3 years before screening;
• \. Screen-positive for drug abuse (except those screen-positive for drug abuse due to concomitant medication);
• \. Positive breath alcohol test (alcohol concentration \>0mg/L);
• \. (Inquiry) who consumed more than 14 units of alcohol per week in the 3 months before screening (1 unit = 17.7 mL ethanol, i.e. 1 unit = 354 mL of 5% beer or 44 mL of 40% liquor or 147 mL of 12% wine), or who could not abstain from alcohol during the study;
• \. (Inquiry) who smoked more than 5 cigarettes per day in the 3 months before screening, or who could not stop using any tobacco products during the study;
• \. (Inquiry) subjects who consumed excessive amounts of tea, coffee and/or caffeine-rich beverages (more than 8 cups, 1 cup =250 mL) per day in the previous 3 months;

Sponsors & Collaborators

• Ganzhou Hemay Pharmaceutical Co., Ltd: lead

Study Sites (1)

Union Hospital of Tongji Medical College; Huazhong University of Science and Technology

Wuhan, Hubei, China

RECRUITING

MeSH Terms

Conditions

Psoriasis

Interventions

Hemay005

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Weiyong Li

  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Zimeng Wang

CONTACT

022-24929667; wangzimeng@hemay.com.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 9, 2024
• First Posted: April 19, 2024
• Study Start: April 28, 2024
• Primary Completion: December 10, 2025
• Study Completion: December 31, 2025
• Last Updated: December 4, 2025

Record last verified: 2025-11

Locations

CN (1)